Shares in Gilead Sciences gained more than 15% on Thursday after details emerged of a closely watched clinical trial of the company's experimental antiviral remdesivir appeared to show promising results in treating COVID-19, reported CNBC.
A Phase III trial run by the University of Chicago found that most of its patients achieved "rapid recoveries in fever and respiratory symptoms" and were discharged in less than a week.
Kathleen Mullane, an infectious diseases specialist at the university, said "the best news is that most of our patients have already been discharged, which is great. We've only had two patients perish."
The study recruited 125 patients with SARS-CoV-2 into Gilead's two late-stage clinical trials, 113 of whom were severely ill.
Clinical trial results involving patients with severe cases of the novel coronavirus are expected this month, while data testing patients with moderate symptoms are expected in May.
To read more NewsPoints articles, click here.